Cancer genetics and therapeutics

205 - Frequency and Characteristics of Large Deletions in Patients with Muir-Torre Syndrome

Previous Eposter
204 - A Platform Independent Method for Calculating Aberrant Cell Fraction from Microarray and NGS Data

Next Eposters
206 - Next-Generation Sequencing Panel Analysis in 2600 Hereditary Cancer Patients
207 - Hepatoblastoma as the Presenting Sign of Beckwith-Wiedemann Syndrome (BWS) and Absence of Other Clinical Features
209 - A Pilot Study Evaluating Genomic and Pharmacogenomic, Variants among Elderly Patients with Colorectal Cancer
211 - Double Heterozygotes and Carriers of Biallelic Pathogenic Variants Identified During Genetic Testing for Hereditary Cancer Risk at a Diagnostic Laboratory
214 - Novel Association of NUP214 Gene Fusions in Acute Myeloid Leukemia
216 - The BAFopathies: A New Way to Conceptualize Disorders of the BAF Chromatin Remodeling Complex
218 - Atypical Presentation of Neurofibromatosis and Melanoma Associated with CDKN2A Gene Deletion  
220 - Lynch Syndrome Families with Breast Cancer: Majority of Observed Mutations Are in MSH6 and PMS2
225 - Delivering Care to the Individuals with Genetic Predisposition to Cancer –  A 20 Month-Experience in GeneHome
231 - “Seeing Stars”: Treatment of Profound Biotinidase Deficiency Identified via Whole Exome Sequencing Restores Vision Loss in 49-Year-Old Male